Please wait a minute...
European Journal of Gynaecological Oncology  2021, Vol. 42 Issue (1): 66-72    DOI: 10.31083/j.ejgo.2021.01.2167
Original Research Previous articles | Next articles
The importance of dysregulated miRNAs on ovarian cysts and epithelial ovarian cancer
Ece Gumusoglu1, Tuba Gunel1, *(), Mohammad Kazem Hosseini1, Nogayhan Seymen2, Taylan Senol3, Uğur Sezerman2, Samet Topuz4, Kılıç Aydınlı5
1Istanbul University, Faculty of Science, Department of Molecular Biology and Genetics, 34134, Istanbul, Turkey
2Acıbadem University, School of Medicine, Department of Basic Sciences, Biostatistics, 34684, Istanbul Turkey
3Istanbul Zeynep Kamil Women and Child Diseases Training and Research Hospital, 34668, Istanbul, Turkey
4Istanbul University, Istanbul Medical Faculty, Department of Obstetrics and Gynecology, 34093, Istanbul, Turkey
5Medicus Healthcare Centre, 34365, Istanbul, Turkey
Download:  PDF(204KB)  ( 276 ) Full text   ( 33 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: Benign ovarian cysts (BOC) are the most common tumors in women of reproductive age. Usually, these cysts are harmless, but, a small number of them occasionally progress to malignancy. Among ovarian malignancies, epithelial ovarian cancer (EOC) comprises 90% and is the most important cause of gynecologic cancer-related deaths. We aimed to identify dysregulated miRNAs in patients with benign ovarian cysts compar to EOC and to healthy individuals (HI). We studied three different sample groups (serum of EOC (n = 8), HI (n = 8), and BOC (n = 8) patients) that contained the highest-quality of RNA. Microarray data were analyzed according to expression of miRNAs and target genes by bioinformatics tools. Results: When compared to EOC samples, 75 miRNAs were dysregulated in BOC samples. Sixty-six miRNAs from BOC were dysregulated when compared to HI samples. Bioinformatics analysis of BOC vs. EOC and BOC vs. HI showed that 46 miRNAs were congruent and their expression alterations were similar (up- or down-regulated). Further analysis showed that these 46 miRNAs are associated to one of three pathways involved in cancer pathogenesis. Conclusion: Several miRNAs might play a role in BOC formation and/or malignant transformation. These dysregulated miRNAs could potentially be a biomarker to distinguish between a completely BOC and one that is malignant or has potential for malignant transformation.
Key words:  Ovarian neoplasms      Ovarian cysts      MicroRNAs      Neoplastic transformation      Epithelial ovarian cancer     
Submitted:  09 June 2020      Revised:  16 October 2020      Accepted:  16 October 2020      Published:  15 February 2021     
Fund: 51472/Scientific Research Projects Coordination Unit of Istanbul University
*Corresponding Author(s):  Tuba Gunel     E-mail:  gunel@istanbul.edu.tr

Cite this article: 

Ece Gumusoglu, Tuba Gunel, Mohammad Kazem Hosseini, Nogayhan Seymen, Taylan Senol, Uğur Sezerman, Samet Topuz, Kılıç Aydınlı. The importance of dysregulated miRNAs on ovarian cysts and epithelial ovarian cancer. European Journal of Gynaecological Oncology, 2021, 42(1): 66-72.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2021.01.2167     OR     https://ejgo.imrpress.com/EN/Y2021/V42/I1/66

[1] Ana Carolline da Silva, Millena Prata Jammal, Renata Margarida Etchebehere, Eddie Fernando Candido Murta, Rosekeila Simões Nomelini. Association of cancer-associated fibroblasts and survival in malignant ovarian neoplasms[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 782-787.
[2] Anita Agrawal, Mariia Karizhenskaia, Joshua Gitlin, Richa Chibbar, Cheng-Han Lee, Rajni Chibbar. An unusual mullerian carcinoma with myoepithelial differentiation (adenoid cystic carcinoma-like) of the ovary: case report[J]. European Journal of Gynaecological Oncology, 2021, 42(4): 811-816.
[3] Mehmet Sait Bakır, Özer Birge, Ceyda Karadag, Selen Doğan, Hasan Aykut Tuncer, Tayup Simsek. Clinicopathological risk factors and survival analysis of ovarian cancer with synchronous endometrial cancer diagnosed after surgery[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 499-505.
[4] Meng-Hui Huang, Yun Han, Qing-Hua Xi, Yun-Feng Jin, Ying-Lei Liu, Yu-Wen Han, Hai-Li Kai, Qian Zhang, Yan-Li Zheng. Exploration on correlation of high DLX2 expression with poor prognosis and cellular proliferation in epithelial ovarian cancers[J]. European Journal of Gynaecological Oncology, 2021, 42(3): 521-529.
[5] Chun-Yu Zhang, Chun-Yan Chen, Hai-Xia Wen, Zi-Feng Song, Ping-Ping Hu. miR-182-5p enhances cisplatin resistance in epithelial ovarian cancer by downregulating GRB2[J]. European Journal of Gynaecological Oncology, 2021, 42(2): 353-359.
[6] Sefa Kurt, Selim Kandemir, Onur Yavuz, Meral Koyuncuoglu, Emine Cagnur Ulukus, Murat Celiloglu. Persistent tubal epithelium in ovaries after salpingectomy[J]. European Journal of Gynaecological Oncology, 2020, 41(6): 919-923.
[7] Yudi Mulyana Hidayat, Gatot Nyarumenteng Adhipurnawan Winarno, Maringan Diapari Lumban Tobing, Arieff Kustiandi, Kemala Isnainiasih Mantilidewi, Sofie Rifayani Krisnadi. The Role of Akt2 and CA-125 Serum Levels as Predictors for Successful Cytoreduction in Epithelial Ovarian Cancer Surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 739-744.
[8] Lingyun Zhai, Lixin Zeng, Hongru Jiang, Wei Li. Effects of a cyclooxygenase-1-selective inhibitor in combination with taxol or cisplatin on cyclin D1, apoptosis, and vascular endothelial growth factor in a xenograft model of ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 779-784.
[9] Ana Carolinne da Silva, Isac Souza Silva Rodrigues, Antônio Carlos Oliveira de Meneses, Eddie Fernando Candido Murta, Rosekeila Simões Nomelini. Ectopic pregnancy concomitant with borderline ovarian tumor[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 810-812.
[10] Gen-Hai Zhu, Kang Wang, Lan Hong, Xin-Hui Fu, Fu-Jin Liu, Hai-Yan Huang. Safety and efficacy of fertility-sparing surgery for an orthotopic xenograft model of epithelial ovarian cancer in nude mice[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 609-616.
[11] Chenchen Zhu, Hanyuan Liu, Zhen Shen, Yanhu Xie, Tianjiao Zhang, Björn Nashan, Dabao Wu, Ying Zhou. Treatment and survival outcomes from epithelial ovarian cancer in women aged 65 years or older[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 415-421.
[12] Emine Karabuk, Burak Karadag, Ceyda Karadag, M. Faruk Kose, M. Murat Naki, E. Nilufer Guler. The outcomes of fertility sparing surgery in epithelial ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 391-395.
[13] Xiaofeng Xu, Xuan Zhou, Yijin Wang, Tao Liu, Jian Fu, Qian Yang, Jun Wu, Huaijun Zhou. Survival-associated transcriptome analysis in ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 455-461.
[14] N. Tug, M. Yassa, M. Akif Sargın, B. Dogan Taymur, K. Sandal, Ertunc Mega. Preoperative discriminating performance of the IOTA-ADNEX model and comparison with Risk of Malignancy Index: an external validation in a non-gynecologic oncology tertiary center[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 200-207.
[15] Can Fang, Yan Zhao, Kezhen Li, Danhui Weng, Peng Wu, Gang Chen, Ding Ma, Juncheng Wei. Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study[J]. European Journal of Gynaecological Oncology, 2020, 41(2): 260-264.
No Suggested Reading articles found!